Recurrent Glioblastoma IDH Wildtype
5
4
4
0
Key Insights
Highlights
Treatment Research
6 treatments under study, led by P134 Cell Injection
Research Leaders
6 sponsors active, led by Beijing Tiantan Hospital
Related Conditions
Often studied with 4 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 5 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (5)
D2C7-IT + 2141-V11 Combination Post-resection in rGBM
Pilot Radioembolisation Clinical Trial Assessing Safety and Efficacy in Recurrent Glioma
[177Lu]Lu-DOTA-EB-RGD2 Therapy in Patients With Recurrent High-grade Glioma
Dosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent Glioblastoma
A Clinical Trial of P134 Cells in Recurrent Glioblastoma
Research Network
Common Treatments
- P134 Cell Injection1
- 177luludotaebrgd21
- 2141 V111
- D2c7it1
- Sirspheres1
Active Sponsors
- Beijing Tiantan Hospital2
- Darell Bigner1
- Rockefeller University1
- Tasly Pharmaceutical Group Co., Ltd1
- Olivia Newton-John Cancer Research Institute1
Top Investigators
Beijing Tiantan Hospital
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Beijing Tiantan Hospital, Capital Medical University, Beijing, P.R.China
Related Conditions
- Recurrent Glioblastoma2
- Glioblastoma Gbm1
- Recurrent Glioblastoma Whograde Iv Glioma1
- Recurrent Highgrade Gliomas1